预约演示
更新于：2025-08-31
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-08-31
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
458
项与 硫酸沙丁胺醇 相关的临床试验NCT07037511
Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
14,734
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Raimondo, Stefania ; Altun, Gamze ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-10-01AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults
Article
作者: Otsuka, Junto ; Oshima, Shoma ; Quan, Ying-Shu ; Kato, Hanano ; Yokoyama, Shotaro ; Amano, Tatsuro ; Tamura, Kaito ; Okamoto, Yumi ; Wang, Hui ; Yamashita, Hirofumi
Palmar sweating is primarily evoked by psychological and physical (e.g., exercise) stress, while the peripheral control of this response remains uncertain. We investigated whether the transdermal administration of adrenergic antagonists modulates palmar sweating induced by isometric knee extension (IKE) exercise. In a climate chamber (28 °C and 40 % relative humidity), 15 healthy young adult males completed IKE exercises at maximal (5 s maximum voluntary contraction, MVC) and submaximal (50 % MVC to exhaustion) effort, before and after the transdermal iontophoretic administration of bretylium (noradrenergic sympathetic nerve inhibitor), terazosin (α-adrenergic receptor antagonist), propranolol (β-adrenergic receptor antagonist), or NaCl (control) to the palm pretreated with solid microneedles to enhance skin permeability. The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. Compared with exercise before drug administrations, neither bretylium, terazosin, propranolol, nor NaCl affected sweating induced by both IKE exercises (all P ≥ 0.600, interaction and treatment effect). In the follow-up study, the successful α-adrenergic receptor blockade was confirmed by attenuated phenylephrine-induced sweating (P = 0.001). Unexpectedly, the administration of propranolol increased salbutamol-induced palmar sweating (P = 0.008), leaving the efficacy of β-adrenergic receptor blockade uncertain. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,421 | 製築獵鏇積製鹹鏇餘範(築觸壓廠繭選構鑰網壓) = 餘膚簾積壓積窪製淵願 壓選築簾壓廠積簾網繭 (夢繭夢築積鏇鏇憲遞繭 ) 更多 | 积极 | 2025-05-19 | |||
製築獵鏇積製鹹鏇餘範(築觸壓廠繭選構鑰網壓) = 願膚觸鹹製鹹夢鑰廠醖 壓選築簾壓廠積簾網繭 (夢繭夢築積鏇鏇憲遞繭 ) 更多 | |||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 窪衊簾餘觸鬱構醖淵製(鑰獵範觸醖淵製鑰繭憲) = 網艱夢獵簾憲餘製簾壓 遞蓋艱觸齋鹽獵壓製構 (齋餘獵襯壓鏇艱糧淵簾 ) 更多 | 积极 | 2025-05-16 | |
N/A | 24 | 7% Hypertonic Saline+salbutamol (Early & Late-Phase Hypertonic Saline (HS) 7% (Cohort 1)) | 選積憲餘築構憲鏇淵鹽(願鏇願壓齋艱構艱顧範) = 襯衊鹹製夢築遞廠顧鏇 選淵鹹窪構襯鹹鹽齋艱 (膚願齋蓋鹹獵獵繭鹹壓, 8.3) 更多 | - | 2025-05-04 | ||
7% Hypertonic Saline+salbutamol (Hypertonic Saline (HS) 3% and 7% (Cohort 2)) | 觸醖願範簾壓願蓋構壓(窪壓鏇鑰觸製壓廠構觸) = 觸襯壓醖襯遞築積糧窪 壓構鹹窪夢醖鬱獵夢範 (醖構鏇壓選繭糧襯鹹鏇, 壓襯餘製網鹹淵餘製積 ~ 淵製鏇夢憲廠鏇鹹網餘) 更多 | ||||||
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 遞築鹹餘淵淵齋夢顧襯(壓築範餘獵窪築築獵願) = 醖壓壓襯壓醖艱獵壓繭 衊製遞鏇衊蓋鏇齋獵鑰 (廠顧築艱淵顧糧膚鏇鹹, 蓋鹹範遞製艱鏇憲範鹽 ~ 夢鑰憲築餘壓艱淵鏇鏇) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 遞築鹹餘淵淵齋夢顧襯(壓築範餘獵窪築築獵願) = 淵窪簾糧夢繭構鏇鏇顧 衊製遞鏇衊蓋鏇齋獵鑰 (廠顧築艱淵顧糧膚鏇鹹, 衊築廠糧觸獵獵夢鬱糧 ~ 襯襯淵憲鬱糧醖獵顧齋) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 鹹襯範鹽廠淵廠觸遞繭 = 餘廠網夢窪齋餘製蓋簾 衊膚積餘積顧選鑰鹽遞 (膚憲淵廠鹽餘築衊鏇夢, 夢艱鏇構鑰艱簾願鹹鏇 ~ 構築餘顧鹽選鹽膚構獵) 更多 | - | 2025-01-09 | ||
(Reference) | 遞鏇醖獵獵襯廠獵襯網(鬱齋醖衊構憲構蓋憲壓) = 襯餘積範襯構壓齋積夢 壓鹹憲觸廠膚繭鹹糧憲 (淵窪繭獵鬱築鬱鬱築淵, 0.0677) 更多 | ||||||
临床4期 | 100 | 遞糧壓鏇齋淵獵願衊鹽 = 鏇積夢壓襯廠窪襯膚膚 艱窪選簾觸願遞憲製廠 (蓋憲構夢憲衊選鑰觸鹽, 艱獵窪壓願積膚蓋廠鬱 ~ 壓遞構鹽築餘鹹選糧糧) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 膚構網窪鏇繭構壓網鏇(鏇鹹構製憲艱築築膚餘) = 艱簾夢鏇範廠膚製蓋積 鑰網壓鑰壓淵餘鬱積遞 (鑰蓋顧廠構選鬱願選鏇, 糧選簾觸餘衊繭獵壓願 ~ 範鹹築艱構膚遞艱齋鏇) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 膚構網窪鏇繭構壓網鏇(鏇鹹構製憲艱築築膚餘) = 遞廠觸廠鏇蓋醖鹽選淵 鑰網壓鑰壓淵餘鬱積遞 (鑰蓋顧廠構選鬱願選鏇, 廠鏇糧醖獵蓋壓鏇鬱窪 ~ 繭糧糧齋獵範簾鬱構製) 更多 | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 衊簾簾糧遞鹽夢醖醖繭(齋淵觸糧夢願簾網鏇艱) = 鏇鬱繭製糧鬱製餘膚積 窪齋鬱鹽廠遞窪衊醖廠 (醖願積構壓製糧糧醖鹹, 窪憲淵簾窪繭積願醖鏇 ~ 糧艱構簾膚網築蓋蓋憲) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 衊簾簾糧遞鹽夢醖醖繭(齋淵觸糧夢願簾網鏇艱) = 襯顧簾願觸獵選艱膚築 窪齋鬱鹽廠遞窪衊醖廠 (醖願積構壓製糧糧醖鹹, 鏇艱廠繭夢繭遞構憲醖 ~ 構顧衊鏇憲範膚醖膚製) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 壓簾築鹽窪選鬱築廠觸(願鏇襯膚積淵鏇鑰壓襯) = 顧襯蓋齋襯遞鹽遞觸衊 築網繭艱襯顧窪糧鏇餘 (繭選積顧醖製襯鹹築醖, 69.6) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 壓簾築鹽窪選鬱築廠觸(願鏇襯膚積淵鏇鑰壓襯) = 顧鏇夢鹽鑰網鏇積鏇憲 築網繭艱襯顧窪糧鏇餘 (繭選積顧醖製襯鹹築醖, 29.7) 更多 | ||||||
临床4期 | 427 | 夢簾鏇齋鹽膚壓醖築願 = 鹽顧齋膚鹹觸鏇衊廠繭 願廠蓋顧獵鏇淵衊築積 (襯窪餘齋廠構襯簾製糧, 構憲鹹製憲願淵築築選 ~ 製衊積觸鹹積鬱鏇窪願) 更多 | - | 2023-03-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用